Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Firstly, let us look at Pfizer's stock performance in recent years. PFE stock has faced a notable decline of 30% from levels of $35 in early January 2021 to around $25 now, vs. an increase of ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry.

The decrease in PFE stock over the last few years has been far from consistent, with annual returns being considerably more volatile than the S&P 500. Returns for PFE stock were 67% in 2021, -10% ...

Pfizer's financial results and stock-market performance might not look great this year, but those won't last forever. ... Is Pfizer Stock a Buy After This $1.25 Billion Investment?

Pfizer's revenue and earnings dropped off a cliff along with its coronavirus-related results as the pandemic started fading, which explains its poor performance over the past 18 months.